Talzenna is currently approved in combination with Xtandi (enzalutamide) for individuals with castration-resistant prostate ...

The stock's fall snapped a four-day winning streak.

On May 21, analyst Geoff Meacham of Citi maintained a Hold rating on Pfizer Inc. (NYSE:PFE), reiterating the price target of ...

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...